Advertisement 2015 ASH Annual Meeting

Syed Abutalib, MD / April 10, 2016 / 2015 ASH Annual Meeting

Selected Abstracts From 2015 ASH Annual Meeting: Part 4

Here is the final installment of selected abstracts from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on Hodgkin lymphoma, follicular lymph...

The ASCO Post / 2015 ASH Annual Meeting

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Dr. Robert Rifkin, Medical Director of Biosimilars at US Oncology Research, moderates a roundtable discussion on Global Perspectives on the Integration of Biosimilars into Oncology Practice, held in c...

Symptom Management

Syed A. Abutalib, MD / March 10, 2016 / 2015 ASH Annual Meeting

Selected Abstracts From 2015 ASH Annual Meeting: Part 3

Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on the topic of anticoagulation and the cancer pa...

Caroline Helwick / March 10, 2016 / 2015 ASH Annual Meeting

CAR-T Cell Therapy May Have Role in Treating Multiple Myeloma

Among the burgeoning options for treating multiple myeloma could be an approach that is proving to be exciting in leukemia: CAR-T (chimeric antigen receptor T cells) therapy. Preliminary results of th...

Syed A. Abutalib, MD / February 25, 2016 / 2015 ASH Annual Meeting

Selected Abstracts From 2015 ASH Annual Meeting: Part 3

Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on newly diagnosed multiple myeloma, relapsed/ref...

myelodysplastic syndromes

Syed A. Abutalib, MD / February 10, 2016 / 2015 ASH Annual Meeting

Selected Abstracts From 2015 ASH Annual Meeting: Part 2

Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting therapeutics in acute leukemias and myelodysp...

Caroline Helwick / February 10, 2016 / 2015 ASH Annual Meeting

Studies Confirm and Extend the Benefits of Ixazomib in Multiple Myeloma

Patients with multiple myeloma now have access to an all-oral regimen, with the recent approval of the oral proteasome inhibitor ixazomib (Ninlaro) in previously treated patients. New pairings for the...

The ASCO Post / 2015 ASH Annual Meeting

Global Perspectives on the Integration of Biosimilars Into Oncology Practice

Matthew Stenger / January 25, 2016 / 2015 ASH Annual Meeting

Phase III Trial Shows Improved Progression-Free Survival With Ibrutinib vs Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma

In aphase III trial reported in The Lancet and at the recent American Society of Hematology Annual Meeting and Exposition, Martin Dreyling, MD, of the European Mantle Cell Lymphoma Network, and collea...

Alice Goodman / January 25, 2016 / 2015 ASH Annual Meeting

Blood Test Can Predict High-Risk Cancers in Patients Treated With CAR-T

Dramatic advances have been made in using genetically engineered chimeric antigen receptor–modified T cells (CAR-T) with anti-CD19 specificity to treat highly refractory hematologic malignancies. The ...

Caroline Helwick / January 25, 2016 / 2015 ASH Annual Meeting

palliative care

Study Confirms Benefit of Triplet vs Doublet in Newly Diagnosed Multiple Myeloma

Triplets should be the standard of care in most newly diagnosed multiple myeloma patients, according to a study that validated a practice that has become common in the United States, though not necess...

myelodysplastic syndromes

Caroline Helwick / January 25, 2016 / 2015 ASH Annual Meeting

Myeloablative Conditioning for Stem Cell Transplantation Remains Standard of Care in Patients With MDS and AML

A randomized trial from the Bone and Marrow Transplant Clinical Trials Network was halted early after concluding that allogeneic stem cell transplantation after a reduced-intensity conditioning regime...

Alice Goodman / January 25, 2016 / 2015 ASH Annual Meeting

Self-Reports Overestimate Mercaptopurine Intake in Childhood Acute Lymphoblastic Leukemia

Mercaptopurine is critical for maintaining remission in childhood acute lymphoblastic leukemia (ALL). However, a study has shown that overreporting of intake is common, and self-reports of intake are ...

Alice Goodman / January 25, 2016 / 2015 ASH Annual Meeting

New Use for CAR-T Cells Post Transplantation

The approach of using genetically engineered chimeric antigen receptor (CAR)-T cells has received much attention for treating leukemias, where it has achieved spectacular long-lasting complete remissi...

Alice Goodman / January 25, 2016 / 2015 ASH Annual Meeting

Venetoclax May Prove to Be Strong Weapon Against Poor-Prognosis Chronic Lymphocytic Leukemia

Venetoclax, the latest entry into the field of treatment of chronic lymphocytic leukemia (CLL), is a powerful investigational therapy that promises to fill an important niche: treatment of high-risk r...

Alice Goodman / January 25, 2016 / 2015 ASH Annual Meeting

Severe Toxicities Seen in Younger Patients Receiving Front-Line Idelalisib for Chronic Lymphocytic Leukemia

Hematologists and patients with chronic lymphocytic leukemia (CLL) are excited about new drugs that have dramatically improved outcomes. But all drugs have side effects, and it is important to be awar...

Alice Goodman / January 25, 2016 / 2015 ASH Annual Meeting

Idelalisib Improves Progression-Free Survival Over Bendamustine Plus Rituximab in Chronic Lymphocytic Leukemia

Idelalisib (Zydelig) combined with bendamustine (Bendeka, Treanda) plus rituximab (Rituxan) was superior to chemotherapy with bendamustine/rituximab plus placebo, reducing the risk of progressive dise...

Caroline Helwick / January 25, 2016 / 2015 ASH Annual Meeting

Rituximab Adds Benefit to Chemotherapy in Adult B-Cell Precursor ALL

The addition of rituximab (Rituxan) to the pediatric-inspired chemotherapy protocol for B-cell precursor acute lymphoblastic leukemia (ALL) significantly improved event-free survival in a large Europe...

Alice Goodman / January 25, 2016 / 2015 ASH Annual Meeting

Could CAR-T Therapy Be Moving Into Lymphoma?

The use of T cells that are genetically engineered to express chimeric antigen receptor (CAR-T) has made headway as an approach to hematologic malignancies, with the best results achieved in leukemia....

Caroline Helwick / January 25, 2016 / 2015 ASH Annual Meeting

Multiple Myeloma in 2015: A Year for the Record Books

Few malignancies have received as much attention, in the way of newly approved drugs, as multiple myeloma did in 2015. In November alone, 3 new agents were approved, bringing the total to 4 for the ye...

The ASCO Post / December 25, 2015 / 2015 ASH Annual Meeting

ASH Awards Inaugural Giuseppe Bigi Memorial Award in Hematopoiesis and Stem Cells to Marilena Ciciarello, PhD

The American Society of Hematology (ASH) named Marilena Ciciarello, PhD, of the University of Bologna, the inaugural recipient of the ASH Giuseppe Bigi Memorial Award for Achievement in Hematopoiesis ...

The ASCO Post / December 25, 2015 / 2015 ASH Annual Meeting

ASH Honors Baseball Hall of Famer With Outstanding Service Award

The American Society of Hematology (ASH) recognized Rod Carew, Baseball Hall of Famer and Advocate for the National Marrow Donor Program (NMDP)/Be the Match, at the 57th ASH Annual Meeting and Exposit...

Hematologic Malignancies

Myelodysplastic Syndromes

Syed A. Abutalib, MD / December 25, 2015 / 2015 ASH Annual Meeting

Selected Abstracts From 2015 ASH Annual Meeting

Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting therapeutics in acute leukemias and myelodyspla...

Alice Goodman / December 25, 2015 / 2015 ASH Annual Meeting

Pediatric Regimen Achieves Higher-Than-Expected Survival in Young Adults With Acute Lymphoblastic Leukemia

Adolescents and younger adults with acute lymphoblastic leukemia (ALL) had superior outcomes on a “pediatric” regimen compared with adult treatment protocols. A multicenter phase II study included pat...

Alice Goodman / December 25, 2015 / 2015 ASH Annual Meeting

Promising Upfront Combination in Older Patients With Acute Lymphoblastic Leukemia

Frontline treatment with the antibody-drug conjugate inotuzumab ozogamicin plus deintensified chemotherapy is a promising option for older patients with Philadelphia chromosome–negative acute lymphobl...

The ASCO Post / December 25, 2015 / 2015 ASH Annual Meeting

ASH Announces Top Trainee Abstracts of 2015 Annual Meeting

The American Society of Hematology (ASH) recognized investigators with the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, ...

Alice Goodman / December 25, 2015 / 2015 ASH Annual Meeting

Midostaurin: A New Standard of Care in Acute Myeloid Leukemia?

Upfront treatment with midostaurin added to standard chemotherapy improved survival compared with placebo plus chemotherapy in high-risk patients with acute myeloid leukemia (AML) characterized by FLT...

Hematologic Malignancies

Caroline Helwick / December 25, 2015 / 2015 ASH Annual Meeting

Issues in Oncology

Alice Goodman / December 25, 2015 / 2015 ASH Annual Meeting

Ibrutinib Bests Standard of Care for Elderly Patients With CLL

First-line treatment with the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) significantly reduced the risk of dying or disease progression compared with chlorambucil (Leukeran) in older tre...

Multiple Myeloma

Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma

The anti-CD38 monoclonal antibody daratumumab (Darzalex) took center stage among multiple myeloma studies presented at the 57th American Society of Hematology Annual Meeting and Exposition. In relaps...

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD / 2015 ASH Annual Meeting

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I study of venetoclax monotherapy in pati...

symptom management

David Henry, MD / 2015 ASH Annual Meeting

David Henry, MD, on Anticoagulants: Expert Perspective

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Sagar Lonial, MD, and Alessandra Tedeschi, MD / 2015 ASH Annual Meeting

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

Sagar Lonial, MD, of the Emory University School of Medicine, and Alessandra Tedeschi, MD, of the Azienda Ospedaliera Niguarda Cà Granda, discuss this international study of ibrutinib vs chlorambucil ...

Sagar Lonial, MD / 2015 ASH Annual Meeting

Sagar Lonial, MD, on Multiple Myeloma: How I Treat Newly Diagnosed Patients

Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.

Sagar Lonial, MD, and Torben Plesner, MD / 2015 ASH Annual Meeting

Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study

Sagar Lonial, MD, of Emory University School of Medicine, and Torben Plesner, MD, of Vejle Hospital, discuss the latest findings on the use of daratumumab in combination with lenalidomide and dexameth...

myelodysplastic syndromes

Mikkael A. Sekeres, MD / 2015 ASH Annual Meeting

Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117

Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses an additional analysis of a phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-...

Kieron Dunleavy, MD / 2015 ASH Annual Meeting

Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial

Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adapted approach using t...

James N. Kochenderfer, MD / 2015 ASH Annual Meeting

James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial

James N. Kochenderfer, MD, of the National Cancer Institute, reports on remissions of multiple myeloma during a trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor ...

James Foran, MD / 2015 ASH Annual Meeting

James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara

James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for cons...

Nathan Hale Fowler, MD / 2015 ASH Annual Meeting

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Nathan Hale Fowler, MD, of MD Anderson Cancer Center, discusses a multicenter trial in which ibrutinib plus rituximab was administered to treatment-naive patients with follicular lymphoma (Abstract 47...

Hagop M. Kantarjian, MD / 2015 ASH Annual Meeting

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-...

S. Vincent Rajkumar, MD / 2015 ASH Annual Meeting

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their cu...

symptom management

Alok A. Khorana, MD / 2015 ASH Annual Meeting

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).

Margaret O'Donnell, MD / 2015 ASH Annual Meeting

Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients

Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).

Craig H. Moskowitz, MD / 2015 ASH Annual Meeting

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182...

Simon Rule, MD / 2015 ASH Annual Meeting

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).

Stephen J. Schuster, MD / 2015 ASH Annual Meeting

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Stephen J. Schuster, MD, of the University of Pennsylvania, discusses the findings of a study of chimeric antigen receptor modified T cells directed against CD19 in patients with relapsed or refractor...

Laurie H. Sehn, MD, MPH / 2015 ASH Annual Meeting

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemother...